Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ximino to treat inflammatory lesions of severe acne vulgaris. It also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial product that reduces amyloid deposits in the tissues and organs; MB-102, a chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; MB-106, a CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, the company develops MB-101 for Glioblastoma multiform (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB 108 for GBM; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101 that is in Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; Cosibelimab for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammato...
Website: fortressbiotech.com



Growth: Good revenue growth rate 20.0%, there is acceleration compared to average historical growth rates 2.9%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -32.3%. On average the margin is improving steadily. Gross margin is high, +67.4%.

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -3.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 152.6% higher than minimum and 37.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 0.3x by EV / Sales multiple , the company can be 94.1% overvalued

Key Financials (Download financials)

Ticker: FBIOP
Share price, USD:  (0.0%)12.63
year average price 7.81  


year start price 6.35 2025-02-12

min close price 5.08 2025-04-14

max close price 12.71 2026-01-23

current price 12.63 2026-02-11
Common stocks: 27 244 474

Dividend Yield:  0.0%
Last revenue growth (y/y):  +20.0%
Last growth of EBITDA (y/y):  +115.4%
Historical revenue growth:  +2.9%
Historical growth of EBITDA:  +39.8%
EV / Sales: 5.4x
Margin (EBITDA LTM / Revenue): -32.3%
Fundamental value created in LTM:
Market Cap ($m): 344
Net Debt ($m): -9
EV (Enterprise Value): 335
Price to Book: 6.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-07-05globenewswire.com

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-14 2025-08-14 2024-11-14 2024-08-13 2024-05-15 2023-09-30 2023-08-14 2023-05-15 2022-11-14 2022-08-11
acceptedDate 2025-11-14 08:46:12 2025-08-14 16:16:41 2025-03-31 16:15:43 2024-11-14 16:40:34 2024-08-13 16:30:43 2024-05-15 16:32:08 2024-03-28 16:49:36 2023-09-29 20:00:00 2023-08-14 16:16:03 2023-05-15 16:16:26 2023-03-31 16:05:28 2022-11-14 16:16:37 2022-08-11 16:08:08 2022-03-28 16:06:55 2021-03-31 16:03:13
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 18M 16M 58M 15M 15M 13M 85M 35M 17M 12M 76M 17M 19M 69M 46M
costOfRevenue 6M 5M 21M 5M 7M 7M 23M 6M 8M 6M 31M 7M 8M 32M 15M
grossProfit 12M 11M 37M 9M 8M 6M 62M 28M 10M 6M 45M 9M 11M 37M 31M
grossProfitRatio 0.674 0.699 0.639 0.561 0.477 0.815 0.553 0.481 0.563 0.596
researchAndDevelopmentExpenses 208 000 8M 57M 9M 13M 25M 106M 20M 32M 40M 135M 30M 33M 129M 64M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 17M 39M 88M 22M 21M 18M 91M 22M 24M 25M 114M 30M 29M 87M 61M
otherExpenses 1M 1M 3M 0 3M -21 000 7M 620 000 395 000 -351 000 0 -669 000 0 10M 0
operatingExpenses 19M 48M 147M 31M 36M 43M 204M 42M 57M 64M 249M 59M 62M 225M 125M
costAndExpenses 24M 53M 168M 37M 43M 50M 227M 49M 64M 71M 279M 67M 70M 257M 140M
interestIncome 736 000 622 000 3M 589 000 734 000 833 000 3M 547 000 715 000 1M 1M 419 000 150 000 649 000 2M
interestExpense 2M 3M 10M 6M 2M -3M 13M 2M 5M 3M 14M 3M 3M 15M 15M
depreciationAndAmortization 1M 1M 4M 3M 1M 2M 6M 3M 1M 2M 9M 2M 2M 7M 5M
ebitda 12M -8M -104M -21M -26M -37M -136M -10M -46M -56M -194M -48M -17M -146M -88M
ebitdaratio 0.705 -0.513 -1.44 -1.755 -2.806 -0.302 -2.64 -4.507 -2.896 -0.876
operatingIncome -7M -36M -110M -22M -28M -37M -142M -14M -50M -59M -204M -50M -51M -189M -94M
operatingIncomeRatio -0.386 -2.222 -1.51 -1.865 -2.806 -0.396 -2.882 -4.708 -3.029 -2.696
totalOtherIncomeExpensesNet 16M 25M -10M -5M -1M 19M -11M 5M -7M 3M -10M -3M -3M 24M -9M
incomeBeforeTax 9M -12M -121M -27M -29M -18M -154M -11M -59M -55M -213M -53M -54M -164M -103M
incomeBeforeTaxRatio 0.502 -0.71 -1.82 -1.935 -1.361 -0.305 -3.411 -4.437 -3.21 -2.856
incomeTaxExpense 26 000 0 312 000 69 000 0 -2M 521 000 141 000 -29M -33M 449 000 -31M 0 473 000 136 000
netIncome 6M 15M -46M -13M -11M -18M -61M -5M -25M -22M -87M -23M -21M -65M -47M
netIncomeRatio 0.332 0.944 -0.88 -0.735 -1.361 -0.145 -1.425 -1.779 -1.363 -1.131
eps 0.13 0.5 -2.69 -0.76 -0.73 -1.03 -8.47 -10.09 -3.36 -0.22 -14.55 -0.25 -0.24 -11.85 -9.75
epsdiluted 0.11 0.45 -0.76 -0.73 -1.03 -10.09 -3.36 -0.22 -0.25 -0.24
weightedAverageShsOut 27M 27M 21M 20M 18M 17M 8M 499 910 7M 102M 6M 89M 89M 5M 5M
weightedAverageShsOutDil 33M 30M 21M 20M 18M 17M 8M 499 910 7M 102M 6M 89M 89M 5M 5M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-31 2024-03-28 2023-03-31 2022-03-28 2021-03-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -7M -10M -12M -15M -14M
ebit -109M -142M -203M -153M -93M
nonOperatingIncomeExcludingInterest -1M -624 000 -517 000 -36M -1M
netIncomeFromContinuingOperations -121M -154M -214M -165M -103M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -56M -69M -95M -65M -47M
epsDiluted -2.69 -8.47 -14.55 -11.85 -9.75

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-14 2025-08-14 2024-11-14 2024-08-13 2024-05-15 2023-09-30 2023-08-14 2023-05-15 2022-11-14 2022-08-11
acceptedDate 2025-11-14 08:46:12 2025-08-14 16:16:41 2025-03-31 16:15:43 2024-11-14 16:40:34 2024-08-13 16:30:43 2024-05-15 16:32:08 2024-03-28 16:49:36 2023-09-29 20:00:00 2023-08-14 16:16:03 2023-05-15 16:16:26 2023-03-31 16:05:28 2022-11-14 16:16:37 2022-08-11 16:08:08 2022-03-28 16:06:55 2021-03-31 16:03:13
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 86M 74M 57M 59M 76M 86M 81M 72M 78M 152M 178M 208M 249M 306M 233M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 86M 74M 57M 59M 76M 86M 81M 72M 78M 152M 178M 208M 249M 306M 233M
netReceivables 18M 16M 10M 11M 11M 10M 15M 8M 17M 28M 28M 29M 29M 24M 25M
inventory 12M 13M 14M 12M 10M 11M 10M 11M 12M 13M 14M 15M 16M 10M 1M
otherCurrentAssets 2M 7M 8M 5M 7M 10M 11M 6M 7M 8M 10M 6M 5M 0 7M
totalCurrentAssets 119M 110M 90M 86M 103M 117M 117M 98M 128M 202M 230M 258M 299M 346M 266M
propertyPlantEquipmentNet 15M 16M 17M 18M 18M 23M 23M 24M 25M 32M 33M 34M 32M 34M 32M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 29M 30M 32M 18M 19M 19M 20M 21M 22M 26M 27M 28M 29M 13M 15M
goodwillAndIntangibleAssets 29M 30M 32M 18M 19M 19M 20M 21M 22M 26M 27M 28M 29M 13M 15M
longTermInvestments 0 1M 2M 0 0 2M 2M 2M 2M 0 3M 0 0 2M 19M
taxAssets 0 0 0 0 0 0 0 -2M -2M 0 -3M 0 0 -2M 0
otherNonCurrentAssets 19M 3M 3M 5M 5M 4M 4M 7M 6M 3M 4M 4M 3M 3M 1M
totalNonCurrentAssets 63M 49M 54M 41M 42M 48M 51M 53M 53M 61M 64M 66M 65M 50M 67M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 181M 160M 144M 127M 146M 165M 168M 151M 181M 264M 294M 324M 364M 397M 333M
accountPayables 19M 20M 32M 34M 38M 42M 35M 45M 49M 66M 57M 56M 54M 47M 11M
shortTermDebt 8M 6M 625 000 4M 5M 10M 9M 5M 15M 10M 10M 11M 10M 5M 6M
taxPayables 1M 984 000 932 000 850 000 806 000 843 000 843 000 84 000 0 722 000 722 000 0 345 000 345 000 136 000
deferredRevenue 0 0 0 0 23M 843 000 0 37M 51M 547 000 728 000 1M 1M 3M 0
otherCurrentLiabilities 27M 30M 5M 32M 31M 35M 31M 10M 15M 53M 47M 38M 40M 34M 27M
totalCurrentLiabilities 54M 58M 71M 70M 76M 88M 85M 97M 129M 129M 128M 106M 105M 101M 52M
longTermDebt 61M 63M 58M 68M 83M 61M 61M 65M 66M 112M 93M 114M 109M 47M 60M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 2M 2M 2M 2M 2M 19M 2M 2M 2M 2M 2M 48M 2M 2M 2M
totalNonCurrentLiabilities 62M 65M 74M 70M 85M 81M 81M 66M 68M 114M 117M 116M 111M 70M 85M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 15M 15M 17M 18M 18M 18M 18M 21M 22M 24M 24M 24M 22M 23M 23M
totalLiabilities 116M 123M 146M 140M 160M 169M 166M 164M 197M 244M 244M 222M 216M 171M 136M
preferredStock 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000
commonStock 31 000 30 000 28 000 28 000 23 000 19 000 15 000 9000 155 000 130 000 110 000 108 000 108 000 101 000 95 000
retainedEarnings -730M -736M -741M -734M -721M -710M -695M -686M -681M -656M -634M -607M -585M -547M -483M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 -3000 0 0 -3000 0 0 0 0 0 0
othertotalStockholdersEquity 786M 780M 755M 739M 733M 702M 699M 693M 669M 662M
totalStockholdersEquity 56M 44M 23M 21M 18M 23M 23M 17M 19M 38M 42M 62M 77M 109M 100M
totalEquity 65M 37M -2M -13M -15M -4M 2M -13M -16M 20M 50M 62M 77M 226M 197M
totalLiabilitiesAndStockholdersEquity 181M 160M 127M 146M 165M 151M 181M 264M 324M 293M
minorityInterest 9M -7M -24M -34M -32M -27M -21M -30M -34M -18M 8M 0 0 117M 97M
totalLiabilitiesAndTotalEquity 181M 160M 144M 127M 146M 165M 168M 151M 181M 264M 294M 324M 293M 397M 333M
totalInvestments 0 1M 2M 0 2M 2M 2M 2M 2M 0 3M 0 0 2M 19M
totalDebt 68M 69M 76M 72M 88M 89M 89M 70M 81M 123M 127M 125M 119M 75M 89M
netDebt -18M -5M 19M 13M 12M 3M 8M -2M 3M -30M -51M -83M -130M -231M -144M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-31 2024-03-28 2023-03-31 2022-03-28 2021-03-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 10M 15M 28M 23M 24M
otherReceivables 171 000 167 000 138 000 678 000 744 000
prepaids 0 0 0 7M 0
totalPayables 33M 36M 58M 48M 12M
otherPayables 932 000 843 000 722 000 345 000 136 000
accruedExpenses 31M 9M 10M 9M 7M
capitalLeaseObligationsCurrent 3M 0 2M 2M 0
capitalLeaseObligationsNonCurrent 15M 18M 22M 21M 23M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 764M 717M 676M 656M 583M
otherTotalStockholdersEquity 0 0 -103 000 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-14 2025-08-14 2024-11-14 2024-08-13 2024-05-15 2023-09-30 2023-08-14 2023-05-15 2022-11-14 2022-08-11
acceptedDate 2025-11-14 08:46:12 2025-08-14 16:16:41 2025-03-31 16:15:43 2024-11-14 16:40:34 2024-08-13 16:30:43 2024-05-15 16:32:08 2024-03-28 16:49:36 2023-09-29 20:00:00 2023-08-14 16:16:03 2023-05-15 16:16:26 2023-03-31 16:05:28 2022-11-14 16:16:37 2022-08-11 16:08:08 2022-03-28 16:06:55 2021-03-31 16:03:13
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome 9M -12M -121M -13M -11M -15M -154M -11M -59M -55M -214M -53M -54M -165M -103M
depreciationAndAmortization 1M 1M 4M -3M 1M 2M 6M 3M 1M 2M 9M 2M 2M 7M 5M
deferredIncomeTax 0 0 0 0 0 0 0 -5M 10M 0 0 0 0 0 0
stockBasedCompensation 3M 17M 33M 0 5M 5M 17M 4M 4M 5M 23M 7M 5M 19M 13M
changeInWorkingCapital -5M -7M -8M -5M -3M 6M -13M -8M 8M 6M -715 000 -267 000 4M 36M -5M
accountsReceivables -2M 3M 4M -12M -712 000 5M 13M 9M 10M 466 000 -5M 83 000 2M 834 000 -10M
inventory 1M -356 000 -4M -519 000 893 000 -374 000 4M 1M 1M 881 000 2M 823 000 84 000 -8M -547 000
accountsPayables -3M -8M -6M 6M -6M 3M -24M -17M -4M 5M 8M 0 0 43M 11M
otherWorkingCapital -740 000 -624 000 -2M 686 000 2M -2M -5M -784 000 549 000 25 000 -6M -1M -577 000 690 000 -5M
otherNonCashItems -15M -27M 12M 585 000 -14M -21M 15M 76 000 3M -1M 3M 874 000 1M -14M 5M
netCashProvidedByOperatingActivities -6M -28M -80M -20M -22M -25M -128M -17M -33M -43M -179M -43M -41M -117M -84M
investmentsInPropertyPlantAndEquipment 0 0 -15M 0 0 0 -63 000 -1M -34 000 0 -3M -1M -307 000 -5M -2M
acquisitionsNet 3M 0 0 0 0 0 0 6M 5M -5M -20M 0 0 57M 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 6M 0 0 0 5M -7M 0 127 000 0
netCashUsedForInvestingActivites 3M 6M 0 0 0 5M -2M -5M -893 000 -307 000
debtRepayment -704 000 -5M -17M 5M 0 -10M -43M -28M 0 0
commonStockIssued 14M 9M 21M 16M 30M 10M 15M 24M 2M 5M
commonStockRepurchased 0 0 0 0 0 0 0 90 000 88 000 0 -1M 0 0 0 -70 000
dividendsPaid -166 000 -166 000 -176 000 -2M -2M -2M -2M -2M -2M -2M
otherFinancingActivites 2M 504 000 -501 000 -4M 30M -979 000 -5000 29M 4M 193 000
netCashUsedProvidedByFinancingActivities 15M 5M 3M 14M 28M -3M -30M 22M 4M 3M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 12M -17M -25M -17M -8M 5M -98M -14M -66M -26M -127M -40M -39M 73M 82M
cashAtEndOfPeriod 87M 76M 59M 61M 78M 86M 83M 75M 89M 155M 181M 211M 251M 308M 235M
cashAtBeginningOfPeriod 76M 93M 83M 78M 86M 81M 181M 89M 155M 181M 308M 251M 290M 235M 153M
operatingCashFlow -6M -28M -80M -20M -22M -25M -128M -17M -33M -43M -179M -43M -41M -117M -84M
capitalExpenditure 0 0 -15M 0 0 0 -8M -1M -34 000 0 -3M -1M -307 000 -16M -7M
freeCashFlow -6M -28M -95M -20M -22M -25M -136M -18M -33M -43M -182M -44M -42M -133M -91M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-31 2024-03-28 2023-03-31 2022-03-28 2021-03-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 -2M -213 000 -12M -5M
netCashProvidedByInvestingActivities -15M -2M -23M 41M -7M
netDebtIssuance -7M -39M 49M -10M -30M
longTermNetDebtIssuance -7M -36M 47M -10M -30M
shortTermNetDebtIssuance 0 -3M 2M 812 000 0
netStockIssuance 83M 81M 42M 172M 218M
netCommonStockIssuance 83M 80M 39M 155M 171M
commonStockIssuance 83M 80M 40M 155M 171M
netPreferredStockIssuance 0 454 000 2M 17M 47M
netDividendsPaid -5M -9M -9M -9M -7M
commonDividendsPaid -694 000 -736 000 -749 000 -749 000 -237 000
preferredDividendsPaid -4M -8M -8M -8M -7M
otherFinancingActivities -163 000 -529 000 -7M -5M -9M
netCashProvidedByFinancingActivities 71M 33M 75M 149M 172M
incomeTaxesPaid 120 000 0 858 000 993 000 0
interestPaid 7M 8M 9M 7M 9M

Earning call transcript

2025 q3
2025-11-12 ET (fiscal 2025 q3)
2024 q4
2025-03-26 ET (fiscal 2024 q4)

SEC forms

Show financial reports only

SEC form 10
2025-11-14 08:46 ET
Fortress Biotech reported for 2025 q3
SEC form 8
2025-11-14 08:35 ET
Fortress Biotech published news for 2025 q3
SEC form 8
2025-11-14 08:35 ET
Fortress Biotech reported for 2025 q3
SEC form 10
2025-08-14 20:16 ET
Fortress Biotech reported for 2025 q2
SEC form 8
2025-08-14 20:10 ET
Fortress Biotech published news for 2025 q2
SEC form 8
2025-08-14 20:10 ET
Fortress Biotech reported for 2025 q2
SEC form 10
2025-05-15 00:00 ET
Fortress Biotech reported for 2025 q1
SEC form 8
2025-05-15 00:00 ET
Fortress Biotech published news for 2025 q1
SEC form 8
2025-05-15 00:00 ET
Fortress Biotech reported for 2025 q1
SEC form 10
2025-03-31 00:00 ET
Fortress Biotech published news for 2024 q4
SEC form 8
2025-03-31 00:00 ET
Fortress Biotech published news for 2024 q4
SEC form 8
2025-03-31 00:00 ET
Fortress Biotech reported for 2024 q4
SEC form 10
2024-11-14 00:00 ET
Fortress Biotech reported for 2024 q3
SEC form 8
2024-11-14 00:00 ET
Fortress Biotech published news for 2024 q3
SEC form 8
2024-11-14 00:00 ET
Fortress Biotech published news for 2024 q3
SEC form 10
2024-08-13 00:00 ET
Fortress Biotech reported for 2024 q2
SEC form 8
2024-08-13 00:00 ET
Fortress Biotech published news for 2024 q2
SEC form 8
2024-08-13 00:00 ET
Fortress Biotech published news for 2024 q2
SEC form 10
2024-05-15 00:00 ET
Fortress Biotech reported for 2024 q1
SEC form 8
2024-05-15 00:00 ET
Fortress Biotech published news for 2024 q1
SEC form 8
2024-05-15 00:00 ET
Fortress Biotech published news for 2024 q1
SEC form 10
2024-03-28 00:00 ET
Fortress Biotech reported for 2023 q4
SEC form 10
2023-11-14 00:00 ET
Fortress Biotech reported for 2023 q3
SEC form 8
2023-11-14 00:00 ET
Fortress Biotech published news for 2023 q3
SEC form 10
2023-08-14 00:00 ET
Fortress Biotech reported for 2023 q2
SEC form 8
2023-08-14 00:00 ET
Fortress Biotech published news for 2023 q2
SEC form 10
2023-05-15 00:00 ET
Fortress Biotech published news for 2023 q1
SEC form 8
2023-05-15 00:00 ET
Fortress Biotech reported for 2023 q1
SEC form 6
2023-04-13 16:05 ET
Fortress Biotech published news for 2023 q1
SEC form 10
2023-03-31 16:05 ET
Fortress Biotech reported for 2022 q4
SEC form 10
2023-03-31 00:00 ET
Fortress Biotech reported for 2022 q4
SEC form 6
2023-03-30 17:28 ET
Fortress Biotech published news for 2022 q4
SEC form 8
2023-03-30 00:00 ET
Fortress Biotech reported for 2022 q4
SEC form 6
2023-03-13 17:28 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-03-03 16:55 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-02-09 17:03 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-06 18:40 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-06 17:57 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-04 21:27 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-04 21:26 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-04 21:25 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-04 21:25 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-04 21:24 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-04 21:24 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-04 21:23 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2022-12-19 08:49 ET
Fortress Biotech published news for 2022 q3
SEC form 6
2022-12-19 08:26 ET
Fortress Biotech published news for 2022 q3
SEC form 6
2022-11-14 17:02 ET
Fortress Biotech published news for 2022 q3
SEC form 10
2022-11-14 16:16 ET
Fortress Biotech reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Fortress Biotech reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Fortress Biotech reported for 2022 q3
SEC form 6
2022-11-04 16:06 ET
Fortress Biotech published news for 2022 q3
SEC form 6
2022-10-28 16:58 ET
Fortress Biotech published news for 2022 q3
SEC form 6
2022-10-24 08:00 ET
Fortress Biotech published news for 2022 q3
SEC form 6
2022-08-25 16:02 ET
Fortress Biotech published news for 2022 q2
SEC form 6
2022-08-11 16:46 ET
Fortress Biotech published news for 2022 q2
SEC form 10
2022-08-11 16:08 ET
Fortress Biotech reported for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Fortress Biotech reported for 2022 q2
SEC form 8
2022-08-11 00:00 ET
Fortress Biotech reported for 2022 q2
SEC form 6
2022-07-22 16:01 ET
Fortress Biotech published news for 2022 q2
SEC form 6
2022-07-11 16:00 ET
Fortress Biotech published news for 2022 q2
SEC form 6
2022-06-27 16:52 ET
Fortress Biotech published news for 2022 q1
SEC form 10
2022-05-12 16:18 ET
Fortress Biotech reported for 2022 q1
SEC form 6
2022-05-12 16:16 ET
Fortress Biotech published news for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Fortress Biotech reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Fortress Biotech reported for 2022 q1
SEC form 6
2022-04-29 17:37 ET
Fortress Biotech published news for 2022 q1
SEC form 6
2022-04-20 17:00 ET
Fortress Biotech published news for 2022 q1
SEC form 10
2022-03-28 16:06 ET
Fortress Biotech published news for 2021 q4
SEC form 6
2022-03-28 08:16 ET
Fortress Biotech published news for 2021 q4
SEC form 10
2022-03-28 00:00 ET
Fortress Biotech published news for 2021 q4
SEC form 8
2022-03-28 00:00 ET
Fortress Biotech published news for 2021 q4
SEC form 6
2021-12-07 08:01 ET
Fortress Biotech published news for 2021 q3
SEC form 6
2021-11-15 16:15 ET
Fortress Biotech published news for 2021 q3
SEC form 10
2021-11-15 16:06 ET
Fortress Biotech published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Fortress Biotech published news for 2021 q3
SEC form 8
2021-11-15 00:00 ET
Fortress Biotech published news for 2021 q3
SEC form 6
2021-10-27 08:16 ET
Fortress Biotech published news for 2021 q3
SEC form 6
2021-10-06 16:14 ET
Fortress Biotech published news for 2021 q3
SEC form 6
2021-09-29 07:45 ET
Fortress Biotech published news for 2021 q2
SEC form 6
2021-09-28 16:10 ET
Fortress Biotech published news for 2021 q2
SEC form 6
2021-09-24 17:19 ET
Fortress Biotech published news for 2021 q2
SEC form 6
2021-08-27 17:02 ET
Fortress Biotech published news for 2021 q2
SEC form 10
2021-08-16 16:14 ET
Fortress Biotech published news for 2021 q2
SEC form 6
2021-08-16 16:08 ET
Fortress Biotech published news for 2021 q2
SEC form 10
2021-08-16 00:00 ET
Fortress Biotech published news for 2021 q2
SEC form 8
2021-08-16 00:00 ET
Fortress Biotech published news for 2021 q2
SEC form 6
2021-07-29 17:01 ET
Fortress Biotech published news for 2021 q2
SEC form 6
2021-07-14 19:17 ET
Fortress Biotech published news for 2021 q2
SEC form 6
2021-06-23 16:15 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-06-17 16:21 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-05-17 16:21 ET
Fortress Biotech published news for 2021 q1
SEC form 10
2021-05-17 16:07 ET
Fortress Biotech published news for 2021 q1
SEC form 10
2021-05-17 00:00 ET
Fortress Biotech published news for 2021 q1
SEC form 8
2021-05-17 00:00 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-04-30 16:02 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-04-20 16:16 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-04-13 17:13 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-04-09 17:29 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-04-01 07:00 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-03-31 16:21 ET
Fortress Biotech published news for 2020 q4
SEC form 10
2021-03-31 16:03 ET
Fortress Biotech published news for 2020 q4
SEC form 6
2021-02-24 08:15 ET
Fortress Biotech published news for 2020 q4
SEC form 6
2020-11-09 16:37 ET
Fortress Biotech published news for 2020 q3
SEC form 10
2020-11-09 16:07 ET
Fortress Biotech published news for 2020 q3